Patents by Inventor Denise Gibo
Denise Gibo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210395324Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: ApplicationFiled: September 2, 2021Publication date: December 23, 2021Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 11136367Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: December 5, 2019Date of Patent: October 5, 2021Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Publication number: 20200095302Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: ApplicationFiled: December 5, 2019Publication date: March 26, 2020Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 10519210Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: January 30, 2019Date of Patent: December 31, 2019Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Publication number: 20190153057Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: ApplicationFiled: January 30, 2019Publication date: May 23, 2019Inventors: WALDEMAR DEBINSKI, HETAL PANDYA, DENISE GIBO
-
Patent number: 10233224Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: September 5, 2017Date of Patent: March 19, 2019Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCESInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Publication number: 20180002394Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: ApplicationFiled: September 5, 2017Publication date: January 4, 2018Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 9771404Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: April 8, 2015Date of Patent: September 26, 2017Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 9296785Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.Type: GrantFiled: April 16, 2010Date of Patent: March 29, 2016Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Publication number: 20150203557Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: ApplicationFiled: April 8, 2015Publication date: July 23, 2015Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 9005600Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: December 18, 2012Date of Patent: April 14, 2015Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Publication number: 20130209541Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.Type: ApplicationFiled: April 16, 2010Publication date: August 15, 2013Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 8362207Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: April 14, 2011Date of Patent: January 29, 2013Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 8343461Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.Type: GrantFiled: August 29, 2008Date of Patent: January 1, 2013Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Jill Wykosky, Denise Gibo
-
Publication number: 20110300099Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: ApplicationFiled: April 14, 2011Publication date: December 8, 2011Inventors: WALDEMAR DEBINSKI, HETAL PANDYA, DENISE GIBO
-
Publication number: 20090123371Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.Type: ApplicationFiled: August 29, 2008Publication date: May 14, 2009Applicant: Wake Forest University Health SciencesInventors: Waldemar Debinski, Jill Wykosky, Denise Gibo
-
Publication number: 20060121539Abstract: Specific, differential expression of EphA2 in both GBM cells and human GBM tumors compared to normal brain are shown. EphA2 serves as a useful molecular marker for cancer in such areas as diagnosis and prognosis. In addition, EphA2 is used in the development of new therapeutics for tumors, such as molecularly targeted drug delivery.Type: ApplicationFiled: October 21, 2005Publication date: June 8, 2006Applicant: The Penn State Research FoundationInventors: Waldemar Debinski, Denise Gibo, Jill Wykosky
-
Publication number: 20050260649Abstract: Fra-1 serves as a target for diagnosing and treating glioblastoma multiforme and related brain cancers. Cancer in a brain tissue sample is detected by analyzing expression of Fra-1 in the sample. Brain cancer is treated by modulating Fra-1 gene expression in cells of the cancer, and by inhibiting angiogenesis associated with the cancer by interfering with Fra-1 binding to a VEGF-D promoter.Type: ApplicationFiled: April 12, 2005Publication date: November 24, 2005Applicant: The Penn State Research FoundationInventors: Waldemar Debinski, Denise Gibo
-
Publication number: 20050255510Abstract: Fra-1 serves as a target for diagnosing and treating glioblastoma multiforme and related brain cancers. Cancer in a brain tissue sample is detected by analyzing expression of Fra-1 in the sample. Brain cancer is treated by modulating Fra-1 gene expression in cells of the cancer, and by inhibiting angiogenesis associated with the cancer by interfering with Fra-1 binding to a VEGF-D promoter.Type: ApplicationFiled: April 12, 2005Publication date: November 17, 2005Applicant: The Penn State Research FoundationInventors: Waldemar Debinski, Denise Gibo
-
Publication number: 20050255511Abstract: Fra-1 serves as a target for diagnosing and treating glioblastoma multiforme and related brain cancers. Cancer in a brain tissue sample is detected by analyzing expression of Fra-1 in the sample. Brain cancer is treated by modulating Fra-1 gene expression in cells of the cancer, and by inhibiting angiogenesis associated with the cancer by interfering with Fra-1 binding to a VEGF-D promoter.Type: ApplicationFiled: April 12, 2005Publication date: November 17, 2005Applicant: The Penn State Research FoundationInventors: Waldemar Debinski, Denise Gibo